CONTENTS

NOTE TO THE READER **1**

LIST OF PARTICIPANTS **3**

PREAMBLE **9**
A. GENERAL PRINCIPLES AND PROCEDURES 9
1. Background 9
2. Objective and scope 10
3. Selection of agents for review 11
4. Data for the *Monographs* 11
5. Meeting participants 12
6. Working procedures 13
B. SCIENTIFIC REVIEW AND EVALUATION 14
1. Exposure data 15
2. Studies of cancer in humans 16
3. Studies of cancer in experimental animals 20
4. Mechanistic and other relevant data 23
5. Summary 26
6. Evaluation and rationale 27
References 31

GENERAL REMARKS **33**

4-AMINOBIPHENYL **41**
1. Exposure Data 41
1.1 Identification of the agent 41
1.2 Uses 41
1.3 Human exposure 41
2. Cancer in Humans 42
2.1 Descriptive studies 42
2.2 Cohort studies 42
2.3 Synthesis 43
3. Cancer in Experimental Animals 43
4. Other Relevant Data 43

4.1 Aromatic amines: metabolism, genotoxicity, and cancer susceptibility. . . . 43
4.2 4-Aminobiphenyl 49
5. Evaluation 50
References 50

BENZIDINE. . . . 53
1. Exposure Data 53
1.1 Identification of the agents. . . . 53
1.2 Uses. . . . 53
1.3 Human exposure 54
2. Cancer in Humans 55
3. Cancer in Experimental Animals 55
4. Other Relevant Data 60
5. Evaluation 61
References 61

DYES METABOLIZED TO BENZIDINE. . . . 65
1. Exposure Data 65
1.1 Identification of the agents. . . . 65
1.2 Uses. . . . 66
1.3 Human exposure 66
2. Cancer in Humans 68
2.1 Cohort Studies 68
2.2 Case–control studies 68
2.3 Synthesis 68
3. Cancer in Experimental Animals 68
4. Other Relevant Data 71
5. Evaluation 71
References 72

4,4′-METHYLENEBIS(2-CHLOROBENZENAMINE). . . . 73
1. Exposure Data 73
1.1 Identification of the agent 73
1.2 Uses. . . . 73
1.3 Human exposure 73
2. Cancer in Humans 75
3. Cancer in Experimental Animals 75
4. Other Relevant Data 79
5. Evaluation 80
References 80

2-NAPHTHYLAMINE 83
1. Exposure Data 83
1.1 Identification of the agent. . . . 83
1.2 Uses. . . . 83
1.3 Human exposure 84
2. Cancer in Humans 85

3. Cancer in Experimental Animals 86
4. Other Relevant Data 86
5. Evaluation 90
References 90

***ortho*-TOLUIDINE 93**
1. Exposure Data 93
   1.1 Identification of the agent 93
   1.2 Uses 93
   1.3 Human exposure 93
2. Cancer in Humans 94
3. Cancer in Experimental Animals 95
4. Other Relevant Data 98
5. Evaluation 98
References 99

AURAMINE AND AURAMINE PRODUCTION 101
1. Exposure Data 101
   1.1 Identification of the agent 101
   1.2 Manufacture and use 101
   1.3 Human exposure 102
2. Cancer in Humans 102
3. Cancer in Experimental Animals 102
4. Other Relevant Data 102
5. Evaluation 104
References 104

MAGENTA AND MAGENTA PRODUCTION 105
1. Exposure Data 105
   1.1 Identification of the agents 105
   1.2 Manufacturing processes 106
   1.3 Human exposure 107
2. Cancer in Humans 107
3. Cancer in Experimental Animals 107
   3.1 Magenta 107
   3.2 CI Basic Red 9 109
4. Other Relevant Data 109
5. Evaluation 109
References 109

BENZO[*a*]PYRENE 111
1. Exposure Data 111
   1.1 Identification of the agent 111
   1.2 Occurrence and exposure 111
2. Cancer in Humans 112
3. Cancer in Experimental Animals 112
   3.1 Skin application 113

3.2 Subcutaneous injection....113
3.3 Oral administration....113
3.4 Intraperitoneal injection....130
3.5 Inhalation....130
3.6 Intrapulmonary injection....130
3.7 Intratracheal administration....130
3.8 Buccal pouch application....131
3.9 Subcutaneous tracheal grafts transplantation....131
3.10 Intramammilary administration....131
3.11 Intracolonic instillation....131
3.12 Intravaginal application....131
3.13 Intrafetal injection....131
4. Other Relevant Data....131
4.1 Metabolism....131
4.2 Diolepoxide mechanism....132
4.3 Radical-cation mechanism....133
4.4 Other activation mechanisms of benzo[*a*]pyrene....133
4.5 Human exposure to PAH-rich mixtures....135
4.6 Synthesis....137
5. Evaluation....137
References....138

COAL GASIFICATION....145
1. Exposure Data....145
2. Cancer in Humans....146
2.1 Cohort studies of coal-gasification workers....146
2.2 Synthesis....146
3. Cancer in Experimental Animals....146
4. Other Relevant Data....149
4.1 Mechanistic evidence relevant to the carcinogenic hazards from occupational exposures during coal gasification....149
4.2 Synthesis....150
5. Evaluation....150
References....150

OCCUPATIONAL EXPOSURES DURING COAL-TAR DISTILLATION....153
1. Exposure Data....153
1.1 Manufacturing process....153
1.2 Occupational exposure....155
2. Cancer in Humans....155
3. Cancer in Experimental Animals....155
4. Other Relevant Data....156
4.1 Mechanistic considerations relevant to the carcinogenic hazards of exposures during coal-tar distillation....156
4.2 Synthesis....158
5. Evaluation....158
References....159

COAL-TAR PITCH 161
1. Exposure Data 161
   1.1 Identification of the agent 161
   1.2 Human exposure 161
2. Cancer in Humans 163
   2.1 Cohort Studies 164
3. Cancer in Experimental Animals 164
4. Other Relevant Data 164
   4.1 Mechanistic considerations relevant to the cancer hazards from exposure during roofing and paving with coal-tar pitch 164
   4.2 Synthesis 165
5. Evaluation 165

References 165

COKE PRODUCTION 167
1. Exposure Data 167
   1.1 Production process 167
   1.2 Human exposure 169
2. Cancer in Humans 169
3. Cancer in Experimental Animals 170
   3.1 Skin application 170
   3.2 Inhalation 171
4. Other Relevant Data 172
   4.1 Mechanistic evidence relevant to the carcinogenic hazard from occupational exposures during coke production 172
   4.2 Synthesis 175
5. Evaluation 175

References 175

MINERAL OILS, UNTREATED OR MILDLY TREATED 179
1. Exposure Data 179
   1.1 Identification of the agent 179
   1.2 Uses 180
   1.3 Human exposure 180
2. Cancer in Humans 181
   2.1 Introduction 181
   2.2 Cancer of the skin/scrotum 181
   2.3 Other cancers 182
   2.4 Synthesis 183
3. Cancer in Experimental Animals 183
   3.1 Earlier studies 184
   3.2 Studies published since the previous evaluation 191
4. Other relevant data 191
   4.1 Humans 191
   4.2 Experimental systems 192
5. Evaluation 193

References 193

SHALE OILS 197
1. Exposure Data 197
   1.1 Identification of the agent 197
   1.2 Uses 197
   1.3 Human exposure 198
2. Cancer in Humans 198
3. Cancer in Experimental Animals 199
   3.1 Raw and spent oil-shale 199
   3.2 Crude shale oils from low-temperature retorting 202
   3.3 Crude shale oils from high-temperature retorting 202
   3.4 Shale-oil fractions 202
   3.5 Shale-oil distillates, blends and other commercial products 203
   3.6 Synthesis 203
4. Other Relevant Data 203
   4.1 Humans 203
   4.2 Experimental systems 204
   4.3 Synthesis 204
5. Evaluation 204
References 205

SOOT, AS FOUND IN OCCUPATIONAL EXPOSURE OF CHIMNEY SWEEPS 209
1. Exposure Data 209
2. Cancer in Humans 211
3. Cancer in Experimental Animals 212
4. Other Relevant Data 212
   4.1 Mechanistic evidence relevant to the carcinogenic hazards from occupational exposure as a chimney sweep 212
   4.2 Synthesis 213
5. Evaluation 213
References 214

OCCUPATIONAL EXPOSURES DURING ALUMINIUM PRODUCTION 215
1. Exposure Data 215
   1.1 Natural occurrence 215
   1.2 Manufacturing processes 215
   1.3 Human exposure 217
2. Cancer in Humans 217
   2.1 Cancer of the urinary bladder 219
   2.3 Synthesis 219
3. Cancer in Experimental Animals 219
4. Other Relevant Data 220
   4.1 Mechanistic evidence relevant to the carcinogenic hazard from occupational exposures during aluminium production 220
   4.2 Synthesis 221
5. Evaluation 221
References 222

AFLATOXINS **225**
1. Exposure Data 225
1.1 Identification of the agents 225
1.2 Sources and uses 226
1.3 Human exposure 227
2. Cancer in Humans 229
2.1 Hepatocellular carcinoma 229
2.2 Synthesis 230
3. Cancer in Experimental Animals 230
3.1 Previous evaluations 230
3.2 Aflatoxin B1 235
3.3 Aflatoxin G1 235
3.4 Synthesis 235
4. Other Relevant Data 236
4.1 Toxicokinetics 236
4.2 Metabolism 237
4.3 Aflatoxin–albumin adducts 239
4.4 Aflatoxin–DNA adducts 240
4.5 Mutagenicity 241
4.6 Molecular lesions 241
4.7 Synthesis 243
5. Evaluation 243
References 244

BENZENE **249**
1. Exposure Data 249
1.1 Identification of the agent 249
1.2 Uses 249
1.3 Human exposure 250
2. Cancer in Humans 257
2.1 Leukemias and lymphomas 258
2.2 Cancer of the lung 261
2.3 Cancer of the kidney 262
2.4 Other cancers 262
3. Cancer in Experimental Animals 262
4. Other Relevant Data 276
4.1 Genetic and related effects 276
4.2 Leukaemogenic potential of benzene 276
5. Evaluation 285
References 285

BIS(CHLOROMETHYL) ETHER AND CHLOROMETHYL METHYL ETHER **295**
1. Exposure Data 295
1.1 Identification of the agents 295
1.2 Uses 295
1.3 Human exposure 296

2. Cancer in Humans 296
3. Cancer in Experimental Animals 297
3.1 BCME 297
3.2 CMME 305
4. Other Relevant Data 305
4.1 Toxicokinetics and toxicity 305
4.2 Genetic and related effects 305
4.3 Mechanistic considerations 306
4.4 Synthesis 306
5. Evaluation 306
References 306

1,3-BUTADIENE 309
1. Exposure Data 309
1.1 Identification of the agent 309
1.2 Use 309
1.3 Human exposure 309
2. Cancer in Humans 311
3. Cancer in Experimental Animals 313
3.1 1,3-Butadiene 313
3.2 Diepoxybutane 313
4. Other Relevant Data 327
4.1 Metabolism of butadiene 327
4.2 Haemoglobin adducts 329
4.3 DNA adducts 330
4.4 Mutagenicity of butadiene and butadiene metabolites 331
4.5 Synthesis 332
5. Evaluation 333
References 333

2,3,7,8-TETRACHLORODIBENZO-*para*-DIOXIN, 2,3,4,7,8-PENTACHLORODIBENZOFURAN, AND 3,3',4,4',5-PENTACHLOROBIPHENYL 339
1. Exposure Data 339
1.1 Identification of the agents 339
1.2 Occurrence and use 340
1.3 Human exposure 341
2. Cancer in Humans 344
2.1 Description of the most informative studies 345
2.2 All cancers combined 347
2.3 Cancer of the lung 347
2.4 Soft-tissue sarcoma 348
2.5 Non-Hodgkin lymphoma 348
2.6 Other cancers 348
2.7 Synthesis 348
3. Cancer in Experimental Animals 349
3.1 *2,3,7,8-Tetrachlorodibenzo*-para-*dioxin* 349

3.2 Dioxin-like compounds 365
4. Other Relevant Data 365
4.1 AhR activation 365
4.2 Mechanisms of carcinogenicity 366
4.3 Dioxin-like compounds 367
4.4 Synthesis 369
5. Evaluation 370
References 371

ETHYLENE OXIDE 379
1. Exposure Data 379
1.1 Identification of the agent 379
1.2 Uses 379
1.3 Human exposure 380
2. Cancer in Humans 382
2.1 Lympho-haematopoietic malignancies 382
2.2 Cancer of the breast 384
2.3 Other cancers 384
2.4 Synthesis 384
3. Cancer in Experimental Animals 384
3.1 Inhalation exposure 384
3.2 Other routes of exposure 388
4. Other Relevant Data 388
4.1 Absorption, distribution, metabolism, and excretion 388
4.2 Genetic and related effects 389
5. Evaluation 395
References 396

FORMALDEHYDE 401
1 Exposure Data 401
1.1 Identification of the agent 401
1.2 Use 401
1.3 Occurrence and exposure 402
2. Cancer in Humans 404
2.1 Cancer of the nasopharynx 404
2.2 Leukaemia 406
2.3 Cancer of the nasal sinuses 408
2.4 Other cancers 409
2.5 Synthesis 409
3. Cancer in Experimental Animals 410
3.1 Inhalation 410
3.2 Oral administration (drinking-water) 410
3.3 Skin application 410
4. Other Relevant Data 417
4.1 Absorption, distribution, metabolism, and excretion 417
4.2 Toxic effects 419

4.3 Genetic and related effects....419
4.4 Mechanistic considerations....427
4.5 Synthesis....430
5. Evaluation....430
References....430

SULFUR MUSTARD....437
1. Exposure Data....437
1.1 Identification of the agent....437
1.2 Uses....437
1.3 Human exposure....438
2. Cancer in Humans....438
3. Cancer in Experimental Animals....440
4. Other Relevant Data....442
4.1 Absorption, distribution, metabolism, and excretion....442
4.2 Genetic and related effects....443
4.3 Synthesis....446
5. Evaluation....446
References....446

VINYL CHLORIDE....451
1. Exposure Data....451
1.1 Identification of the agent....451
1.2 Uses....451
1.3 Human exposure....451
2. Cancer in Humans....454
2.1 Angiosarcoma of the liver....455
2.2 Hepatocellular carcinoma....455
2.3 Cancer of the lung....456
2.4 Malignant neoplasms of connective and soft tissue....456
2.5 Other cancers....457
2.6 Synthesis....457
3. Cancer in Experimental Animals....457
3.1 Inhalation exposure....458
3.2 Oral administration....458
3.3 Subcutaneous and intraperitoneal injection....458
3.4 Transplacental administration and perinatal exposure....458
3.5 Carcinogenicity of metabolites....467
4. Other Relevant Data....467
4.1 Kinetics and metabolism – studies in humans....467
4.2 Kinetics and metabolism – studies in animals....469
4.3 Reaction with cellular macromolecules....470
4.4 Synthesis....472
5. Evaluation....473
References....473

ISOPROPYL ALCOHOL MANUFACTURE BY THE STRONG-ACID PROCESS 479
1. Exposure Data 479
   1.1 Manufacturing processes 479
   1.2 Human exposure 479
2. Cancer in Humans 480
   2.1 Cohort studies 480
   2.2 Case–Control Studies 481
3. Cancer in Experimental Animals 481
4. Other Relevant Data 481
   4.1 Absorption, distribution, metabolism, and excretion 481
   4.2 Genetic and related effects 483
   4.3 Toxicity relevant to carcinogenicity 483
   4.4 Synthesis 483
5. Evaluation 484
References 484

MISTS FROM STRONG INORGANIC ACIDS 487
1. Exposure Data 487
   1.1 Manufacturing processes 487
   1.2 Human exposure 487
2. Cancer in Humans 489
   2.1 Cohort studies 489
   2.2 Case–control studies 491
3. Cancer in Experimental Animals 493
4. Other Relevant Data 493
5. Evaluation 493
References 493

OCCUPATIONAL EXPOSURES DURING IRON AND STEEL FOUNDING 497
1. Exposure Data 497
   1.1 Manufacturing process 497
   1.2 Human exposures 497
2. Cancer in Humans 504
   2.1 Cohort studies 504
   2.2 Case–control studies 504
   2.3 Synthesis 505
3. Cancer in Experimental Animals 505
4. Other Relevant Data 505
   4.1 Mechanistic evidence relevant to the carcinogenic hazards from occupational exposures during iron and steel founding 505
   4.2 Synthesis 505
5. Evaluation 505
References 506

OCCUPATIONAL EXPOSURE AS A PAINTER 509
1. Exposure Data 509
   1.1 Description of paint products 509
   1.2 Human exposure 518
2. Cancer in Humans 519
   2.1 Cancer of the lung 519
   2.2 Mesothelioma 521
   2.3 Cancer of the urinary bladder 521
   2.4 Childhood leukaemia 522
   2.5 Lympho-haematopoietic cancers 523
   2.6 Other cancers 523
   2.7 Synthesis 523
3. Cancer in Experimental Animals 524
4. Other Relevant Data 524
   4.1 Toxicokinetics and metabolism 524
   4.2 Genetics and related effects 526
   4.3 Susceptible populations 530
   4.4 Synthesis 531
5. Evaluation 531
References 531

OCCUPATIONAL EXPOSURES IN THE RUBBER-MANUFACTURING INDUSTRY 541
1. Exposure Data 541
   1.1 Manufacturing process 541
   1.2 Chemicals used in the rubber-production process 542
   1.3 Human exposure 543
2. Cancer in Humans 546
   2.1 Cancer of the bladder 546
   2.2 Leukaemia 547
   2.3 Malignant lymphoma including multiple myeloma and other lymphopoietic cancers 548
   2.4 Cancer of the lung 549
   2.5 Cancer of the larynx 550
   2.6 Cancer of the stomach 550
   2.7 Cancer of the oesophagus 551
   2.8 Cancer of the prostate 552
   2.9 Other cancers 552
3. Cancer in Experimental Animals 552
4. Other Relevant Data 552
5. Evaluation 559
References 559

LIST OF ABBREVIATIONS 563

CUMULATIVE CROSS INDEX TO *IARC MONOGRAPHS* 567

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word 'risks' in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.